Full-Time

Associate Customer Insights Manager

Updated on 9/13/2026

Dexcom

Dexcom

5,001-10,000 employees

Markets real-time CGM devices and analytics

Compensation Overview

$91.4k - $152.3k/yr

Company Does Not Provide H1B Sponsorship

Remote in USA

Remote

Remote within the United States; travel of 5–10% is required.

Bachelor's

Category
Business & Strategy (1)
Required Skills
Microsoft Office
Market Research
Data Visualization
Quantitative Research
Machine Learning
CRM
Data Analysis
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to Dexcom

See people who can refer or advise you

Requirements
  • A minimum of 5 years of experience planning and executing qualitative and quantitative market research projects in pharmaceutical, medical technology/medical device, or consumer packaged goods organizations.
  • First-hand experience integrating brand market research methodologies in support of brand planning and execution plans.
  • Exceptional written and oral communication skills, with the ability to translate data into compelling stories and influence stakeholders through clear, insight-led recommendations.
  • Strong analytical skills, including quantitative data analysis and working knowledge of advanced research methods such as conjoint, discrete choice modeling, price elasticity, and segmentation.
  • Strong attention to detail and ability to ensure accuracy, consistency, and quality across research deliverables.
  • Proven ability to collaborate effectively with internal stakeholders, external vendors, and cross-functional partners while building positive working relationships.
  • Strong project management and organizational skills, with the ability to manage multiple priorities and execute projects with appropriate supervision.
  • Ability to identify and prioritize key research questions, adapt quickly to shifting priorities, and learn new business issues with agility.
  • Strong command of Microsoft Office software, including advanced use of PowerPoint and Excel.
  • Command of basic statistics theory.
  • Typically requires a Bachelor's degree and a minimum of 5–8 years of related experience.
Responsibilities
  • Under the guidance of the Customer Insights Director, lead primary qualitative and quantitative research projects, including clarifying market research objectives, designing research methodology, developing questionnaires and discussion guides, programming surveys, analyzing data, and preparing summative reports personally or with external partners.
  • Support or lead project types including creative concept testing, messaging and communications testing, brand tracking, brand equity measurement, market landscape, and market opportunity assessment.
  • Work with internal stakeholders and external research partners to ensure successful methodology development and fieldwork execution.
  • Lead logistical aspects of research initiatives and vendor management, including screener development, respondent recruitment, project proposal requests, vendor setup, invoice processing, and document control.
  • Develop and present clear storylines with insightful data and provide recommendations by integrating data with existing team knowledge.
  • Analyze syndicated and secondary research and extract insights to support and enhance primary research projects.
  • Identify common themes across available research data and synthesize them into actionable insights.
  • Collaborate cross-functionally to drive business results.
  • Apply artificial-intelligence-enabled and machine-learning-supported approaches to synthesize high-volume unstructured inputs, including social listening, app reviews, Amazon reviews, and verbatim feedback, into normalized insight themes.
  • Understand and comply with documented quality standards and requirements.
Desired Qualifications
  • Experience in the diabetes space.
  • Experience with syndicated and secondary research.
  • Knowledge of the United States payer and insurance landscape.
  • Experience using artificial-intelligence-supported synthesis, automated theme coding, or machine-learning-enabled listening tools to analyze large volumes of qualitative or unstructured customer feedback.
  • Familiarity with integrating emerging data sources such as social listening, app and marketplace reviews, customer relationship management data, dashboards, or external intelligence platforms to create faster, more scalable, decision-ready insights.

Dexcom develops continuous glucose monitoring systems to help people manage diabetes. Its core Dexcom G6 uses a wearable sensor and transmitter to stream real-time glucose data to a display or smartphone, with factory calibration and no routine finger-prick calibrations. It differentiates itself with a complete ecosystem including analytics software like Dexcom CLARITY and subscription services that share data with clinicians and caregivers. Its goal is to improve quality of life by providing accurate, easy-to-use glucose monitoring and actionable insights.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1999

Get referred to Dexcom

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Dexcom raised 2026 revenue guidance to $5.18-$5.25 billion after Q2 growth.
  • Q2 2026 revenue hit $1.31 billion, with gross margin expanding to 64.1%.
  • Dexcom expects about 50% US customer conversion to G7 15 Day by year-end 2026.

What critics are saying

  • Abbott’s FreeStyle Libre keeps pressuring Dexcom pricing, reimbursement, and US share in 2026.
  • Dexcom’s 2025 Abbott truce ends courtroom leverage, leaving product execution as defense.
  • If Abbott undercuts G7 adoption, Dexcom’s premium-margin story collapses by 2027.

What makes Dexcom unique

  • Dexcom G7 15 Day won Health Canada authorization on 2026-07-13.
  • Dexcom now connects CGM data with Health2Sync across Australia and Singapore.
  • Dexcom still leads on premium CGM accuracy, wear time, and app connectivity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Remote Work Options

Flexible Work Hours

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Business Wire
Aug 31st, 2026
Quentin Blackford to join Align Technology Board of Directors.

Quentin Blackford to join Align Technology Board of Directors. Andrea L. Saia to Retire After 13 Years of Service Quentin Blackford TEMPE, Ariz. & SAN JOSE, Calif.-(BUSINESS WIRE)-Align Technology, Inc. ("Align") (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign(R) System of clear aligners, iTero(TM) intraoral scanners, and exocad(TM) CAD/CAM software for digital orthodontics and restorative dentistry, today announced that its Board of Directors has appointed Quentin Blackford, President and Chief Executive Officer of iRhythm Technologies, as a director effective immediately and announced the retirement of Andrea Saia effective September 23, 2026. "We are pleased to welcome Quentin Blackford to our Board," said Kevin Conroy, Chairman of the Board of Align Technology. "Quentin is an exceptional leader whose accomplishments in global healthcare, medical technology, and digital innovation speak for themselves. His breadth of experience, strategic judgment, and commitment to advancing patient care will be tremendous assets to Align as we continue to shape the future of digital dentistry around the world." Mr. Blackford currently serves as President and Chief Executive Officer of iRhythm Technologies, a leading digital healthcare company focused on advancing cardiac care. He has served in this role since 2021. Before joining iRhythm, Mr. Blackford served as Chief Operating Officer of Dexcom, where he helped lead the company's global operations, corporate strategy, and international growth initiatives. Previously, he held senior finance and leadership positions at NuVasive and Zimmer Holdings. Mr. Blackford currently serves on the board of Alphatec Holdings and is a Certified Public Accountant (inactive). He earned dual Bachelor of Science degrees in Accounting and Business Administration from Grace College. Since joining the Board in 2013, Ms. Saia has played an important role in supporting Align's growth and transformation as a global medical device and digital dentistry leader. Her insights and counsel have contributed to the Board's oversight of the Company's strategic priorities, governance practices, and long-term growth initiatives. The Board and management team extend their sincere appreciation for her dedicated service and many contributions to Align. "Andrea has been an exceptional member of our Board and a trusted advisor to management," said Joe Hogan, president and CEO of Align Technology. "Her deep expertise, thoughtful counsel, and unwavering commitment to strong governance have helped guide Align through a period of significant growth and innovation. On behalf of the Board and the entire Align team, I want to thank Andrea for her many contributions and years of dedicated service." Mr. Blackford will be included in the company's slate of director nominees in the proxy statement for Align's 2027 Annual Meeting of Shareholders. In connection with Mr. Blackford's appointment, the Board increased its size to 11 directors. Effective upon Ms. Saia's resignation from the Board in September 2026, the size of the Board will decrease and again be comprised of ten directors. About Align Technology, Inc. Align Technology designs and manufactures the Invisalign(R) System, the most advanced clear aligner system in the world, iTero(TM) intraoral scanners and services, and exocad(TM) CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 302.0 thousand doctor customers and are key to accessing Align's 600 million consumer market opportunity worldwide. Over the past 29 years, Align has helped doctors treat approximately 23.5 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align(TM) Digital Platform, its integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit www.aligntech.com for more information. For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com. Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.

TechDay
Aug 24th, 2026
Dexcom, Health2Sync partner on diabetes care in Asia.

Dexcom, Health2Sync partner on diabetes care in Asia. Mon, 24th Aug 2026 (Today) Dexcom and Health2Sync have formed a partnership focused on diabetes care in Australia and Singapore, linking glucose monitoring with digital chronic disease management. The partnership aims to support more connected care for people living with diabetes and their healthcare providers in both markets. It also reflects a broader push to expand digital health tools across Asia-Pacific. Health2Sync operates a digital chronic disease management platform that supports about 1.7 million users across the region. The company has built a presence in several Asian markets by offering tools that help people with diabetes and healthcare teams manage long-term care through digital services. Dexcom is known for its continuous glucose monitoring systems, which track glucose levels for people living with diabetes. The tie-up with Health2Sync reflects growing demand for connected healthcare technologies that support care coordination, simplify clinical workflows and enable more tailored approaches to chronic disease management. Regional push The deal gives Dexcom another partnership in Asia-Pacific as digital health companies seek to integrate monitoring devices with software platforms used by patients and clinicians. Australia and Singapore are both exploring greater use of remote monitoring and data-driven management for chronic conditions. Diabetes remains a major long-term health issue across the region, driving demand for systems that connect patient data with clinical decision-making. Companies in the sector have increasingly focused on linking devices, apps and care teams rather than offering standalone products. Health2Sync's scale in the region may give Dexcom access to a wider digital care network, while Dexcom's monitoring products add a stream of glucose data that can be incorporated into patient management. The companies have not disclosed commercial terms or product integration details. The announcement did not specify which Dexcom products or Health2Sync services would be included first in Australia and Singapore. It also did not say when any integrated offering would become available to users or healthcare providers. Company comments Both companies framed the partnership around a shared view that diabetes care can benefit from more connected management models. They said the arrangement is intended to help healthcare professionals and people living with diabetes access smarter, more connected ways to manage the condition. No financial details were released. The companies also did not outline any regulatory steps, local distribution arrangements or clinical partnerships tied to the agreement. More information is expected later. For now, the main disclosed fact is that Dexcom and Health2Sync are aligning their diabetes-related offerings across Australia and Singapore.

Ticker Report
Aug 21st, 2026
Silvant Capital Management LLC Makes New Investment in DexCom, Inc. $DXCM

Silvant Capital Management LLC purchased a new stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 79,562 shares of the medical device company’s stock, valued at approximately $5,359,000. Other large investors have also recently modified their holdings of the company. Reflection Asset Management acquired a new […]

Yahoo Finance
Aug 12th, 2026
DexCom rallies 52.5% in three months as margins expand and earnings beat estimates

DexCom shares have surged 52.5% over the past three months, significantly outpacing the broader market's 2.4% gain and its medical sector's 10.4% rise. The rally followed strong second-quarter results. Revenue increased 13.1% year-over-year to $1.31 billion, whilst adjusted earnings of 70 cents per share beat consensus estimates of 61 cents. US revenues rose 11% to $933.4 million, and international revenues jumped 19% to $375 million. Margin expansion bolstered the growth story. Adjusted gross margin reached 64.1%, up 400 basis points year-over-year, whilst adjusted operating margin improved 590 basis points to 25.1%. DexCom now trades at 30.7 times forward earnings, above its sub-industry average of 27.3 times. The premium valuation means future gains will depend on sustained earnings delivery and market access expansion rather than multiple expansion.

Yahoo Finance
Jul 31st, 2026
DexCom secures coverage for 7M patients, raises growth guidance after Q2 2026 results

DexCom reported 12% organic revenue growth in Q2 2026, driven by record customer acquisition and market share gains. The company raised full-year guidance by over 50 basis points despite a projected $15 million foreign exchange headwind. The CONNECT trial showed 1.6% A1C improvement for non-insulin type 2 diabetes users, supporting reimbursement expansion. DexCom secured coverage for over 7 million non-insulin patients across the four largest US commercial pharmacy benefit managers. The company acquired Nutrisense to integrate nutrition-focused AI insights into its product ecosystem. DexCom executed $600 million of its $1 billion share repurchase programme during the quarter. Gross margins improved 400 basis points year-over-year to 64.1%, driven by manufacturing efficiencies. The company targets converting approximately 50% of US customers to its G7 15-day system by year-end 2026.